Contraindicated (1)bortezomib will raise the amount or impact of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, resulting in heart failure as a consequence of systolic dysfunction. fluconazole will raise the stage or impact of bortezomib by impacting hepatic/intestinal https://ralstoni555ugr7.westexwiki.com/user